Exelixis, Inc.
EXEL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000939767
In the last 90 days, Exelixis, Inc. insiders filed 0 open-market purchases and 1 sale; 760 institutions reported holding it in 13F filings for Q2 2026, worth $14.1B in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Exelixis, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 1 filing
- 1 insider, $526.5K in total
- Insiders trading
- 1
- Net value
- −$526.5K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Exelixis, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Beckerle Mary C | Director | 16,079 | Aug 12, 2026 | 4 |
| Wyszomierski Jack L | Director | 284,384 | Jun 3, 2026 | 3 |
| Eckhardt Sue Gail | Director | 16,079 | Jun 3, 2026 | 3 |
| Caligan Partners LP | Director, Other: See Remarks | 1,553,262Indirect | May 29, 2026 | 2 |
| Johnson David Edward | Director | 1,553,262Indirect | May 29, 2026 | 2 |
| Poste George | Director | 127,199 | May 29, 2026 | 2 |
| Papadopoulos Stelios | Director | 1,197,595 | May 29, 2026 | 2 |
| Freire Maria C | Director | 109,186 | May 29, 2026 | 2 |
| Smith Julie | Director | 28,957 | May 29, 2026 | 2 |
| Oliver Bob | Director | 29,487 | May 29, 2026 | 3 |
| Heyman Tomas J. | Director | 50,649 | May 29, 2026 | 1 |
| Aftab Dana | EVP, Research and Development | 594,741 | May 28, 2026 | 10 |
| Haley Patrick J. | EVP, Commercial | 357,638 | May 22, 2026 | 6 |
| Morrissey Michael | President and CEO | 2,004,327Indirect | May 19, 2026 | 6 |
| Senner Christopher J. | EVP and CFO | 952,317 | May 19, 2026 | 4 |
| Hefti Brenda | SVP and General Counsel | 106,762 | May 19, 2026 | 4 |
| Hessekiel Jeffrey | EVP & General Counsel | 693,396 | May 16, 2025 | 0 |
| Peterson Amy C. | EVP Prod Dev & Med Aff & CMO | 465,393 | May 16, 2025 | 0 |
| Garber Alan M | Director | 35,703 | Mar 25, 2024 | 0 |
| Wright Jacqueline | Director | 51,756 | Jun 2, 2023 | 0 |
| Goodman Vicki L | EVP, Prod Dev & Med Aff &CMO | 307,654 | Apr 5, 2023 | 0 |
| Feldbaum Carl B | Director | 18,701 | Feb 10, 2023 | 0 |
| Lamb Peter | EVP, Scientific Strategy & CSO | 410,958 | Dec 16, 2022 | 0 |
| Marchesi Vincent T | Director | 93,989 | May 27, 2022 | 0 |
| Willsey Lance | Director | 424,415 | May 27, 2022 | 0 |
| Schwab Gisela | Pres, Prod Dev & Med Aff & CMO | 689,078 | Jul 28, 2021 | 0 |
| Cohen Charles | Director | 261,375 | Jul 8, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 28, 2022 (view filing) | Feb 25 | 3 days | Haley Patrick J.EVP, Commercial | SSale | −31.2K | $19.53 | −$610.1K | −13.6%198.5K after | |
| Feb 24, 2022 (view filing) | Feb 22 | 2 days | Papadopoulos SteliosDirector | SSale | −84.5K | $19.56 | −$1.65M | −6.5%1.22M after | |
| Feb 24, 2022 (view filing) | Feb 22 | 2 days | Feldbaum Carl BDirector | SSale | −20.0K | $19.49 | −$389.8K | −70.1%8.52K after | |
| Feb 4, 2022 (view filing) | Feb 3 | 1 day | Haley Patrick J.EVP, Commercial | SSale | −60.0K | $17.91 | −$1.07M | −19.7%245.2K after | |
| Dec 17, 2021 (view filing) | Dec 15 | 2 days | Lamb PeterEVP, Scientific Strategy & CSO | SSale | −47.5K | $17.44 | −$828.4K | −11.6%363.2K after | |
| Nov 26, 2021 (view filing) | Nov 24 | 2 days | Haley Patrick J.EVP, Commercial | SSale | −17.2K | $17.25 | −$297.3K | −6.8%237.8K after | |
| Nov 23, 2021 (view filing) | Nov 19 | 4 days | Feldbaum Carl BDirector | SSale | −20.0K | $17.62 | −$352.4K | −70.1%8.52K after | |
| Nov 17, 2021 (view filing) | Nov 15 | 2 days | Lamb PeterEVP, Scientific Strategy & CSO | SSale | −47.5K | $18.09 | −$859.3K | −10.4%411.2K after | |
| Nov 3, 2021 (view filing) | Nov 1 | 2 days | Hessekiel JeffreyEVP and General Counsel | SSale | −5.12K | $22.03 | −$112.7K | −0.8%632.8K after | |
| Oct 15, 2021 (view filing) | Oct 15 | Same day | Lamb PeterEVP, Scientific Strategy & CSO | SSale | −47.5K | $21.92 | −$1.04M | −10.4%411.2K after | |
| Oct 15, 2021 (view filing) | Oct 15 | Same day | Hessekiel JeffreyEVP and General Counsel | SSale | −12.9K | $22.02 | −$283.7K | −2.0%637.9K after | |
| Sep 17, 2021 (view filing) | Sep 16 | 1 day | Haley Patrick J.EVP, Commercial | SSale | −25.0K | $20.36 | −$509.0K | −8.2%281.0K after | |
| Sep 17, 2021 (view filing) | Sep 15 | 2 days | Lamb PeterEVP, Scientific Strategy & CSO | SSale | −47.5K | $20.46 | −$971.9K | −10.9%389.5K after | |
| Aug 18, 2021 (view filing) | Aug 16 | 2 days | Lamb PeterEVP, Scientific Strategy & CSO | SSale | −55.0K | $18.44 | −$1.01M | −12.4%389.5K after | |
| Jul 16, 2021 (view filing) | Jul 15 | 1 day | Lamb PeterEVP, Scientific Strategy & CSO | SSale | −60.0K | $17.47 | −$1.05M | −13.3%389.5K after |